As seen in Figure 2, there is a specific pathway that these pharmaceutical drugs take to be able to intercept the molecular mechanisms of breast cancer with hormonal receptors (ER and PR) or membrane receptors (HER2). Here, ERBB2 is linked to breast carcinoma.